iStrip Update

Timestrip PLC
21 February 2008


TIME.L

                          Timestrip plc ('Timestrip')

                     iStrip's continued commercial progress


Timestrip is pleased to announce that its iStrip label technology continues to
be well received by its target market and is making excellent commercial
progress.

Following the successful trial announced in November 2007, DHL Healthcare
Logistics have placed initial orders for iStrips to be used as part of their
cold chain logistics operations. Initial sales have also been made to
distributors in the UK and North America, whose end customers include a leading
global pharmaceuticals company, which is using the iStrip with materials being
shipped for clinical trials.

In order to meet the anticipated demand for the technology, the production of
iStrips for use with products at case/pallet level is being scaled up with a
sub-contracted partner in Europe. The volume of re-orders from distributors and
the repeat purchase patterns, whilst still modest in value, are extremely
encouraging.

In addition to these distributor agreements, Timestrip has received a high level
of interest in the iStrip from worldwide distributors who are looking at
incorporating the technology into their established and extensive portfolios of
cold chain solutions. Timestrip is also close to finalising the manufacturing
capability to produce a unit level label for application to individual vaccine
vials.

The Company continues to collaborate with Seattle based non-profit organisation,
PATH to evaluate the acceptability of the case-level iStrip within the context
of vaccine distribution in a developing country setting. PATH is an
international, global health organization that creates sustainable, culturally
relevant solutions that enable communities worldwide to break longstanding
cycles of poor health.


Paul Freedman, CEO of Timestrip, commented:

'We are delighted at the progress being made with our iStrip technology on both
the commercial and the development sides. We have delivered the technology on
schedule and are extremely pleased that we are already having successes with it.
I look forward to reporting further progress in due course'


The iStrip is a patent pending label developed by Timestrip plc that is capable 
of recording whether a wide range of temperature sensitive products, including 
vaccines, have been accidentally frozen during transport or storage.


For more information, please contact:

Paul Freedman/Reuben Isbitsky, Joint CEOs, Timestrip plc         01462 440 700
Shane Dolan, Biddicks                                            020 7448 1000
Fergus Marcroft, Evolution Securities                            020 7071 4300




                      This information is provided by RNS
            The company news service from the London Stock Exchange